Overview

This trial is active, not recruiting.

Condition chronic lymphocytic leukemia
Sponsor Northwell Health
Start date December 2005
End date January 2019
Trial size 90 participants
Trial identifier NCT01110863, 05-05-096, GAC # 0117

Summary

By ingesting a non-radioactive and non-toxic compound "heavy water" for 6 weeks, the DNA of newly developed cells in the body of subjects with B-cell chronic lymphocytic leukemia can be labeled and followed by performing routine blood draws at specified time intervals. By using mass spectrometric analysis we can measure how quickly new B-CLL cells are generated in the bone marrow and how quickly they leave the blood, a measure of cell turnover. This will help us to better understand the unique characteristics of this disease process.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Observational model cohort
Time perspective prospective
Arm
Chronic Lymphocytic Leukemia

Primary Outcomes

Measure
Characterization of the Proliferating Compartment in B-CLL Patients and in Healthy Aging Subjects
time frame: 1 year

Eligibility Criteria

Male or female participants at least 18 years old.

Inclusion Criteria: - 18 years of age, - Patients must be willing to contribute the required amount of blood without compromising their well being, - Participants must be willing to be contacted in the future. Exclusion Criteria: - Pregnancy, - Patients who are known to be anemic, with a hemoglobin < 8, - Patients who are known to be infected with HIV.

Additional Information

Official title Characterization of Proliferating Compartment in B-Cell Patients and in Healthy Aging Subjects
Principal investigator Nicholas Chiorazzi, MD
Description By ingesting a non-radioactive and non-toxic compound "heavy water" for 6 weeks, the DNA of newly developed cells in the body of subjects with B-cell chronic lymphocytic leukemia (B-CLL) can be labeled and followed by performing routine blood draws at specified time intervals. By using mass spectrometric analysis we can measure how quickly new B-CLL cells are generated in the bone marrow and how quickly they leave the blood, a measure of cell turnover. This will help us to better understand the unique characteristics of this disease process.
Trial information was received from ClinicalTrials.gov and was last updated in November 2016.
Information provided to ClinicalTrials.gov by Northwell Health.